JP2021536483A5 - - Google Patents
Info
- Publication number
- JP2021536483A5 JP2021536483A5 JP2021512856A JP2021512856A JP2021536483A5 JP 2021536483 A5 JP2021536483 A5 JP 2021536483A5 JP 2021512856 A JP2021512856 A JP 2021512856A JP 2021512856 A JP2021512856 A JP 2021512856A JP 2021536483 A5 JP2021536483 A5 JP 2021536483A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024111028A JP2024138422A (ja) | 2018-09-06 | 2024-07-10 | ウイルス感染症の治療のための組成物及び方法 |
Applications Claiming Priority (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862727821P | 2018-09-06 | 2018-09-06 | |
| US62/727,821 | 2018-09-06 | ||
| US201862746865P | 2018-10-17 | 2018-10-17 | |
| US62/746,865 | 2018-10-17 | ||
| US201862782119P | 2018-12-19 | 2018-12-19 | |
| US62/782,119 | 2018-12-19 | ||
| US201962788386P | 2019-01-04 | 2019-01-04 | |
| US62/788,386 | 2019-01-04 | ||
| US201962813463P | 2019-03-04 | 2019-03-04 | |
| US62/813,463 | 2019-03-04 | ||
| US201962815235P | 2019-03-07 | 2019-03-07 | |
| US62/815,235 | 2019-03-07 | ||
| US201962832992P | 2019-04-12 | 2019-04-12 | |
| US62/832,992 | 2019-04-12 | ||
| US201962840899P | 2019-04-30 | 2019-04-30 | |
| US62/840,899 | 2019-04-30 | ||
| US201962852075P | 2019-05-23 | 2019-05-23 | |
| US62/852,075 | 2019-05-23 | ||
| US201962859983P | 2019-06-11 | 2019-06-11 | |
| US62/859,983 | 2019-06-11 | ||
| US201962873678P | 2019-07-12 | 2019-07-12 | |
| US62/873,678 | 2019-07-12 | ||
| US201962890475P | 2019-08-22 | 2019-08-22 | |
| US62/890,475 | 2019-08-22 | ||
| PCT/US2019/050018 WO2020051498A1 (en) | 2018-09-06 | 2019-09-06 | Compositions and methods for the treatment of viral infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024111028A Division JP2024138422A (ja) | 2018-09-06 | 2024-07-10 | ウイルス感染症の治療のための組成物及び方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021536483A JP2021536483A (ja) | 2021-12-27 |
| JPWO2020051498A5 JPWO2020051498A5 (https=) | 2022-09-13 |
| JP2021536483A5 true JP2021536483A5 (https=) | 2022-09-13 |
| JP7520816B2 JP7520816B2 (ja) | 2024-07-23 |
Family
ID=69722788
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512856A Active JP7520816B2 (ja) | 2018-09-06 | 2019-09-06 | ウイルス感染症の治療のための組成物及び方法 |
| JP2024111028A Pending JP2024138422A (ja) | 2018-09-06 | 2024-07-10 | ウイルス感染症の治療のための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024111028A Pending JP2024138422A (ja) | 2018-09-06 | 2024-07-10 | ウイルス感染症の治療のための組成物及び方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20210228727A1 (https=) |
| EP (1) | EP3846846A4 (https=) |
| JP (2) | JP7520816B2 (https=) |
| KR (1) | KR20210079278A (https=) |
| CN (2) | CN113194983B (https=) |
| AU (3) | AU2019336230B2 (https=) |
| BR (1) | BR112021004266A2 (https=) |
| CA (1) | CA3111803A1 (https=) |
| CR (1) | CR20210166A (https=) |
| EC (1) | ECSP21023859A (https=) |
| IL (1) | IL281277B2 (https=) |
| MA (1) | MA53558A (https=) |
| MX (1) | MX2021002569A (https=) |
| PH (1) | PH12021550822A1 (https=) |
| SG (1) | SG11202103313RA (https=) |
| TW (1) | TWI840407B (https=) |
| WO (1) | WO2020051498A1 (https=) |
| ZA (1) | ZA202102158B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210079278A (ko) | 2018-09-06 | 2021-06-29 | 시다라 세라퓨틱스, 인코포레이티드 | 바이러스 감염의 치료를 위한 조성물 및 방법 |
| TWI861205B (zh) * | 2019-09-06 | 2024-11-11 | 美商席達拉醫療有限公司 | 用於治療病毒感染之組合物及方法 |
| US11253534B2 (en) | 2020-03-23 | 2022-02-22 | Sabine Hazan | Method of preventing COVID-19 infection |
| US11744866B2 (en) | 2020-03-18 | 2023-09-05 | Sabine Hazan | Methods of preventing and treating COVID-19 infection with probiotics |
| US11278520B2 (en) | 2020-03-31 | 2022-03-22 | Sabine Hazan | Method of preventing COVID-19 infection |
| AU2021241498B2 (en) * | 2020-03-23 | 2024-08-01 | Sabine HAZAN | Methods of preventing and treating COVID-19 infection |
| CN113801138B (zh) * | 2020-06-12 | 2024-11-29 | 博瑞生物医药（苏州）股份有限公司 | 一种一锅法制备辛酸拉尼米韦中间体的方法 |
| EP4192510A1 (en) | 2020-08-06 | 2023-06-14 | Cidara Therapeutics, Inc. | Methods for the synthesis of protein-drug conjugates |
| US20230364251A1 (en) | 2020-08-06 | 2023-11-16 | Cidara Therapeutics, Inc. | Methods for the synthesis of protein-drug conjugates |
| WO2022133281A1 (en) * | 2020-12-17 | 2022-06-23 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of human immunodeficiency virus |
| US20240285786A1 (en) * | 2021-03-11 | 2024-08-29 | Cidara Therapeutics, Inc. | Protein-drug conjugates for antiviral therapy |
| WO2023125806A1 (zh) * | 2021-12-30 | 2023-07-06 | 苏州爱科百发生物医药技术有限公司 | 用于预防和治疗病毒感染的偶联物及其用途 |
| JP2026508522A (ja) * | 2023-03-01 | 2026-03-11 | シダラ セラピューティクス インコーポレーテッド | インフルエンザ感染を処置するための方法 |
| WO2025002421A1 (zh) * | 2023-06-29 | 2025-01-02 | 上海爱科百发生物医药技术股份有限公司 | 用于预防和治疗病毒感染的偶联物及其用途 |
| WO2025119337A1 (zh) * | 2023-12-08 | 2025-06-12 | 苏州拓界医药有限公司 | 一种抗病毒偶联物 |
| WO2025157263A1 (zh) * | 2024-01-26 | 2025-07-31 | 浙江养生堂天然药物研究所有限公司 | 偶联物及其制备方法和用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ335368A (en) | 1996-11-14 | 2001-08-31 | Biota Scient Management | Macromolecular compound with one or more neuraminidase binders, binds to the active site of influenza virus neuraminidase |
| US6495580B1 (en) | 1998-01-29 | 2002-12-17 | Viropharma Incorporated | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
| AUPP913999A0 (en) | 1999-03-12 | 1999-04-01 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
| SG122814A1 (en) | 1999-06-28 | 2006-06-29 | Janssen Pharmaceutica Nv | Respiratory syncytial virus replication inhibitors |
| AUPR879701A0 (en) * | 2001-11-09 | 2001-12-06 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
| CA2495266A1 (en) | 2002-08-09 | 2004-02-19 | Viropharma Incorporated | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| JP2008530132A (ja) | 2005-02-14 | 2008-08-07 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法 |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| AU2006279304A1 (en) | 2005-08-19 | 2007-02-22 | Endocyte, Inc. | Multi-drug ligand conjugates |
| MX2009012343A (es) | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| EP2395992A2 (en) | 2009-02-10 | 2011-12-21 | The Scripps Research Institute | Chemically programmed vaccination |
| CN103068378B (zh) * | 2010-05-10 | 2016-07-06 | 中央研究院 | 具有抗流感活性的扎那米韦膦酸酯同类物及其制备方法 |
| MA34392B1 (fr) | 2010-06-24 | 2013-07-03 | Gilead Sciences Inc | Pyrimidines en tant qu'agents antiviraux |
| RS55609B1 (sr) * | 2011-04-13 | 2017-06-30 | Bristol Myers Squibb Co | Fc fuzioni proteini koji sadrže nove linkere ili aranžmane |
| US8871756B2 (en) | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| US9834597B2 (en) | 2012-09-21 | 2017-12-05 | The Regents Of The University Of California | Modified FC polypeptides, FC conjugates, and methods of use thereof |
| BR112015008325B1 (pt) | 2012-10-16 | 2022-01-25 | Janssen Sciences Ireland Uc | Compostos antivirais contra o rsv, seu uso e composição farmacêutica que os compreende |
| EP3385277A1 (en) | 2013-03-15 | 2018-10-10 | F. Hoffmann-La Roche AG | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
| AR096891A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
| CN105705167A (zh) | 2013-07-25 | 2016-06-22 | 诺华股份有限公司 | 合成的apelin多肽的生物缀合物 |
| JP6211195B2 (ja) | 2013-08-12 | 2017-10-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 呼吸器合胞体ウイルス感染症の処置および予防のための新規アザ−オキソ−インドール |
| TWI671299B (zh) | 2014-04-14 | 2019-09-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 作為ｒｓｖ抗病毒化合物之螺脲化合物 |
| WO2017046625A1 (en) * | 2015-06-25 | 2017-03-23 | Cube Biotech Gmbh | New chelators for affinity purification of recombinant proteins |
| WO2018006063A1 (en) | 2016-07-01 | 2018-01-04 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of bacterial infections |
| US20230190950A1 (en) * | 2017-01-06 | 2023-06-22 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of bacterial infections |
| AU2019218128A1 (en) | 2018-02-09 | 2020-09-17 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
| KR20210079278A (ko) * | 2018-09-06 | 2021-06-29 | 시다라 세라퓨틱스, 인코포레이티드 | 바이러스 감염의 치료를 위한 조성물 및 방법 |
| EP3982994A4 (en) | 2019-06-13 | 2023-10-04 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of respiratory syncytial virus |
| AU2020291469A1 (en) | 2019-06-13 | 2022-02-10 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of human immunodeficiency virus |
| TWI861205B (zh) | 2019-09-06 | 2024-11-11 | 美商席達拉醫療有限公司 | 用於治療病毒感染之組合物及方法 |
| US20240174730A1 (en) | 2021-02-25 | 2024-05-30 | Cidara Therapeutics, Inc. | Variant fc domains and uses thereof |
| US20240285786A1 (en) | 2021-03-11 | 2024-08-29 | Cidara Therapeutics, Inc. | Protein-drug conjugates for antiviral therapy |
-
2019
- 2019-09-06 KR KR1020217010062A patent/KR20210079278A/ko not_active Ceased
- 2019-09-06 BR BR112021004266-0A patent/BR112021004266A2/pt unknown
- 2019-09-06 MA MA053558A patent/MA53558A/fr unknown
- 2019-09-06 TW TW108132329A patent/TWI840407B/zh active
- 2019-09-06 MX MX2021002569A patent/MX2021002569A/es unknown
- 2019-09-06 JP JP2021512856A patent/JP7520816B2/ja active Active
- 2019-09-06 IL IL281277A patent/IL281277B2/en unknown
- 2019-09-06 CN CN201980072811.3A patent/CN113194983B/zh active Active
- 2019-09-06 CR CR20210166A patent/CR20210166A/es unknown
- 2019-09-06 CA CA3111803A patent/CA3111803A1/en active Pending
- 2019-09-06 AU AU2019336230A patent/AU2019336230B2/en active Active
- 2019-09-06 CN CN202511543229.4A patent/CN121338028A/zh active Pending
- 2019-09-06 WO PCT/US2019/050018 patent/WO2020051498A1/en not_active Ceased
- 2019-09-06 EP EP19857366.9A patent/EP3846846A4/en active Pending
- 2019-09-06 SG SG11202103313RA patent/SG11202103313RA/en unknown
-
2021
- 2021-03-05 US US17/193,923 patent/US20210228727A1/en not_active Abandoned
- 2021-03-30 ZA ZA2021/02158A patent/ZA202102158B/en unknown
- 2021-04-01 PH PH12021550822A patent/PH12021550822A1/en unknown
- 2021-04-06 EC ECSENADI202123859A patent/ECSP21023859A/es unknown
- 2021-04-21 US US17/236,722 patent/US11833213B2/en active Active
-
2023
- 2023-09-11 US US18/464,421 patent/US12569565B2/en active Active
- 2023-12-07 AU AU2023278077A patent/AU2023278077B2/en active Active
-
2024
- 2024-07-10 JP JP2024111028A patent/JP2024138422A/ja active Pending
-
2025
- 2025-11-26 AU AU2025271348A patent/AU2025271348A1/en active Pending